EverSource Wealth Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

EverSource Wealth Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.13K	Sell	4,216 -413	-9%	-$1.81K	﹤0.01%	3096
2025 Q4	$24K	Sell	4,629 -211	-4%	-$1.08K	﹤0.01%	2268
2025 Q3	$25.3K	Buy	4,840 +291	+6%	+$1.52K	﹤0.01%	2185
2025 Q2	$17.4K	Buy	4,549 +4,152	+1,046%	+$10.7K	﹤0.01%	2406
2025 Q1	$2.28K	Buy	397 +382	+2,547%	+$2.26K	﹤0.01%	2865
2024 Q4	$75	Buy	+15	New	+$77	﹤0.01%	3590
2022 Q2	–	Sell	-213	Closed	-$1K	–	1703
2022 Q1	$1K	Hold	213	–	–	﹤0.01%	1622
2021 Q4	$1K	Buy	+213	New	+$1.62K	﹤0.01%	1672

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EverSource Wealth Advisors's ALDX Position: Q1 2026 in Review

EverSource Wealth Advisors reduced its Aldeyra Therapeutics (ALDX) stake by 8.9% in Q1 2026, selling an estimated $1.81K and leaving 4,216 shares worth $7.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3096.

EverSource Wealth Advisors first reported a position in ALDX in Q4 2021 and has held it in 8 quarters since. The position peaked at $25.3K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

EverSource Wealth Advisors held 4,216 shares of Aldeyra Therapeutics worth $7.13K as of Q1 2026.
EverSource Wealth Advisors sold 413 Aldeyra Therapeutics shares in Q1 2026, an estimated $1.81K.
Aldeyra Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3096 holding.
EverSource Wealth Advisors first reported a position in Aldeyra Therapeutics in Q4 2021 and has held it in 8 quarters since.
EverSource Wealth Advisors's Aldeyra Therapeutics position peaked at $25.3K in Q3 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.